相关实验视频

Updated: Jan 20, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

代谢功能障碍与脂肪性肝病相关,心脏代谢多病症和死亡率:来自英国生物银行的证据

Can Shen¹, Rong Yang¹, Yiheng Zhou¹

¹General Practice Ward/International Medical Center Ward, Teaching and Research Section of General Practice, General Practice Research Institute, General Practice Medical Center, West China Hospital of Sichuan University, 37 Guoxue Road, Chengdu, 610041, China.

Clinical research in cardiology : official journal of the German Cardiac Society

|January 19, 2026

概括

与代谢功能障碍相关的脂肪性肝病 (MASLD) 显著增加心脏代谢性疾病 (CMD),多病症 (CMM) 和死亡率的风险. 在MASLD的早期干预对于预防这些严重的健康结果至关重要.

科学领域:

肝病学肝病学是一种肝病学.
心脏病学心脏病学
代谢疾病代谢疾病

背景情况:

与代谢功能障碍相关的脂肪性肝病 (MASLD) 和心脏代谢多病症 (CMM) 代表着重大的全球健康挑战.
MASLD对单个心脏代谢疾病 (CMD),CMM和整体死亡率的确切影响需要进一步阐明.

研究的目的:

调查MASLD与发展单个CMD,CMM和全因死亡率的风险之间的关联.
探索MASLD如何影响从单个CMD到CMM的进展和死亡率.
确定CMD和CMM在MASLD和死亡率之间的关系中的中介作用.

主要方法:

对376,087名英国生物库参与者 (37-73岁) 的前性分析.
CMM定义为≥2个同时存在的CMD (中风,缺血性心脏病,2型糖尿病).
通过肝纤维化得分评估MASLD的严重程度;使用Cox模型和结构方程建模.

主要成果:

在无CMD个体中,MASLD与单个CMD (HR 1.94),CMM (HR 3.40) 和死亡率 (HR 1.21) 的更高风险相关.
MASLD增加了 CMM 的进展风险 (HR 1.95) 和死亡率 (HR 1.11).
风险随着MASLD的严重程度而升级;CMD和CMM调解了MASLD对死亡率的影响.

结论:

MASLD显著与CMD,CMM和死亡率的风险增加有关.
针对MASLD的预防策略可能会减轻CMD,CMM的发病率和相关死亡率.

关键词:

心脏代谢性疾病心脏代谢性疾病心脏代谢多病态性肝纤维化得分肝纤维化得分代谢功能障碍与脂肪性肝病相关.死亡率死亡率死亡率

更多相关视频

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

相关概念视频

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

This article describes the use of oleic acid-induced HepG2 cells as a model for metabolic dysfunction-associated steatotic liver...

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction, hepatic gene expression changes, and liver histopathological alterations that resemble human MASLD, including fibrosis that progresses to advanced fibrosis stage 3. This model can be used in studies of MASLD pathophysiology and in pre-clinical studies of new therapies.

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Here, we present how to generate a non-alcoholic fatty liver disease (NAFLD)-associated Hepatocellular Carcinoma (HCC) zebrafish model to study the impact of cholesterol surplus on liver microenvironment and immune cell...

The Evidence for Evolution

The Evidence for Evolution

Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

This protocol offers a systematic framework for the establishment of ovarian cancer organoids from different disease stages and addresses the challenges of patient-specific variability to increase yield and enable robust long-term expansion for subsequent applications. It includes detailed steps for tissue processing, seeding, adjusting media requirements, and immunofluorescence staining.

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...